This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.
The objectives of this study are: 1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV). 2. To evaluate the safety and tolerability of AA administered intravenously.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
A sterile, solution containing 500 mg ascorbic acid per mL
Virginia Commonwealth University
Richmond, Virginia, United States
Concentration of Ascorbic Acid (µM) in plasma
Time frame: 1 day
Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system
Time frame: 1 day
Changes from Baseline in clinical laboratory and vital signs to discharge
Time frame: 1 day
Changes from pre-dose physical exam findings to discharge
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.